Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  01:57 2022-08-09 pm EDT
194.48 USD   -3.84%
11:48aJPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
10:28aNovartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
06:02aBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3 Trial

06/30/2022 | 05:52am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BEIGENE, LTD.
11:48aJPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
10:28aNovartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
06:02aBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
BU
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05ANALYST RECOMMENDATIONS : Eli Lilly, KLA, Kellogg, Epam Systems, BeiGene...
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 394 M - -
Net income 2022 -1 619 M - -
Net cash 2022 2 960 M - -
P/E ratio 2022 -16,6x
Yield 2022 -
Capitalization 20 926 M 20 926 M -
EV / Sales 2022 12,9x
EV / Sales 2023 9,06x
Nbr of Employees 8 500
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 202,24 $
Average target price 275,30 $
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-25.35%20 926
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375